Chidamide and Anlotinib act synergistically in Jurkat cells by inhibiting the Hippo signaling pathway
Background: T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive hematologic malignancy characterized by drug resistance, relapse and poor prognosis. Chidamide, a histone deacetylase inhibitor, has shown epigenetic therapeutic potential in T-ALL, but its efficacy is limited and acquired drug...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2026-03-01
|
| Serie: | Biochemistry and Biophysics Reports |
| Soggetti: | |
| Accesso online: | http://www.sciencedirect.com/science/article/pii/S2405580826000294 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|